Custom Services Tailored for You
Biorbyt offers a range of personalized services, including antibody development, peptide synthesis, protein expression, and antibody conjugation.
Biorbyt: Discover the power of Virus-Like Particles (VLPs) in healthcare innovation. Learn how these nanoscale, non-infectious particles revolutionize vaccines, drug delivery, and gene therapy with unmatched safety and efficacy.
VLPs are nanoscale particles that look like viruses but are not infectious. They are composed of viral proteins that self-assemble into structures similar to a virus, which can include capsid proteins or enveloped virus-like structures. This feature allows them to interact with the human immune system in a manner similar to natural viruses, making them incredibly effective as a foundation for vaccine development and drug delivery systems.
VLPs are already making a significant impact in the vaccine industry. They have been used in successful vaccines against hepatitis B and human papillomavirus (HPV), providing a safe and effective way to prevent these infections. VLP-based vaccines are being researched for other diseases, including influenza, dengue, and even emerging pathogens like the Zika virus. Because VLPs do not carry viral genetic material, they offer a highly safe alternative to traditional vaccines, minimizing the risk of side effects.
VLPs can be engineered to deliver drugs directly to target cells, improving the effectiveness of treatments while reducing side effects. This is especially useful in cancer therapy, where targeted delivery of chemotherapeutic agents can minimize damage to healthy tissues. By modifying VLPs with specific ligands, they can be directed to cancer cells, making treatment more efficient and tailored to the patient’s needs.
In gene therapy, VLPs are used as delivery vectors to transport therapeutic genes to specific cells. This approach is particularly promising for treating genetic disorders, where correcting the faulty genes can significantly improve patient outcomes. VLPs’ ability to penetrate cells without triggering a strong immune response makes them ideal carriers for genetic material.
The potential applications of VLPs are vast, and ongoing research continues to uncover new possibilities. Their versatility, safety, and effectiveness make them a cornerstone of modern biotechnology. Harness the power of VLPs to drive innovation in your field with our high-quality, customizable solutions designed to meet the highest standards of modern science. Explore Biorbyt‘s VLP product range below.
Product name | Cat No. |
---|---|
Recombinant Human Claudin-3 (CLDN3)-VLPs (Active) | ORB1674366 |
Human CLDN18.2 protein | ORB865262 |
Human MS4A1-VLPs Protein | ORB1478133 |
Human SSTR2-VLPs Protein | ORB1478128 |
Human MS4A1-VLPs Protein | ORB1478133 |
Mouse Cldn18-VLPs Protein | ORB1478123 |
We gladly support you by keeping you updated on our latest products and the developments around our services.